These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26738466)

  • 1. Product Exclusivity Granted by the U.S. Food and Drug Administration.
    Novack GD
    Ocul Surf; 2016 Jan; 14(1):74-6. PubMed ID: 26738466
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
    Rivera DR; Hartzema AG
    Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 4. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary supplements: rationale for regulation.
    Nutr Rev; 1993 Oct; 51(10):310-2. PubMed ID: 8302490
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 8. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 9. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 10. Labeling and manufacturing standards proposed for all dietary supplements.
    Horrigan B; Block B
    Altern Ther Health Med; 2003; 9(3):22. PubMed ID: 12776471
    [No Abstract]   [Full Text] [Related]  

  • 11. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 12. AVMA legislation: partial solution to drug availability problem.
    Gloyd JS
    J Am Vet Med Assoc; 1993 Apr; 202(7):1055-6. PubMed ID: 8473213
    [No Abstract]   [Full Text] [Related]  

  • 13. Professional drug labeling.
    Terry M
    J Am Vet Med Assoc; 1993 May; 202(10):1711-2;discussion 1713-7. PubMed ID: 8514591
    [No Abstract]   [Full Text] [Related]  

  • 14. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA to tighten labeling on long acting opioids.
    McCarthy M
    BMJ; 2013 Sep; 347():f5581. PubMed ID: 24030791
    [No Abstract]   [Full Text] [Related]  

  • 16. Ophthalmologists need to focus on extra-label drug use initiative.
    Gelatt KN
    J Am Vet Med Assoc; 1993 Aug; 203(4):497-8. PubMed ID: 8407498
    [No Abstract]   [Full Text] [Related]  

  • 17. Implications for the FDA/Center for Veterinary Medicine (CVM).
    Geyer RE
    J Am Vet Med Assoc; 1993 May; 202(10):1718-23. PubMed ID: 8514592
    [No Abstract]   [Full Text] [Related]  

  • 18. Current FDA policy on use of human-labeled drugs in animals.
    Teske RH
    J Am Vet Med Assoc; 1993 May; 202(10):1632-3;discussion 1634. PubMed ID: 8514570
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.